XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2022
Summary of Significant Accounting Policies  
Schedule of disaggregation of revenue by major source

Three Months Ended June 30, 

Six Months Ended June 30, 

    

2022

    

2021

    

2022

    

2021

Biopharma/Pharma

$

51,728

$

45,489

$

94,739

$

87,877

Animal Health

 

9,562

 

8,394

 

16,356

 

17,394

Reproductive Medicine

2,863

2,308

5,360

4,204

Total revenues

$

64,153

$

56,191

$

116,455

$

109,475

Schedule of geographical revenues, by origin

Three Months Ended June 30, 

Six Months Ended June 30, 

    

2022

    

2021

    

2022

    

2021

Americas

$

34,893

$

29,135

$

62,771

$

56,870

Europe, the Middle East, and Africa (EMEA)

 

16,854

 

15,043

 

33,041

 

29,251

Asia Pacific (APAC)

 

12,406

 

12,013

 

20,643

 

23,354

Total revenues

$

64,153

$

56,191

$

116,455

$

109,475

Schedule of net loss per share

The following shows the amounts used in computing net loss per share (in thousands except per share data):

Three Months Ended June 30, 

Six Months Ended June 30, 

    

2022

    

2021

    

2022

    

2021

Net loss

$

(9,177)

$

(5,389)

$

(22,581)

$

(8,916)

Paid-in-kind dividend on Series C convertible preferred stock

 

(2,000)

 

(2,000)

 

(4,000)

 

(4,196)

Net loss attributable to common shareholders

$

(11,177)

$

(7,389)

$

(26,581)

$

(13,112)

Weighted average common shares issued and outstanding - basic and diluted

48,792,559

45,757,532

49,467,691

44,786,403

Basic and diluted net loss per share

$

(0.23)

$

(0.16)

$

(0.54)

$

(0.29)

Schedule of number of shares excluded from the computation of diluted loss per share

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

Three Months Ended June 30, 

Six Months Ended June 30, 

    

2022

    

2021

    

2022

    

2021

Stock options

 

3,457,046

 

5,855,953

3,845,882

 

5,908,632

Restricted stock units

709,481

339,212

709,481

339,212

Series C convertible preferred stock

5,552,919

5,283,411

5,552,919

5,283,411

Conversion of 2026 Senior Notes

3,422,780

3,422,780

Conversion of 2025 Senior Notes

 

599,954

 

4,810,002

599,954

 

4,810,002

 

13,742,180

 

16,288,578

14,131,016

 

16,341,257